This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yakes, F. M. Articles by Hellerqvist, C. G. Search for Related Content PubMed PubMed Citation Articles by Yakes, F. M. Articles by Hellerqvist, C. G.

CM101 Treatment Overrides Tumor-induced Immunoprivilege Leading to Apoptosis¹

Departments of Biochemistry [F. M. Y., B. D. W., F. S., C. G. H.] and Biology [H-P. Y., C. E. C.], Vanderbilt University, Nashville, Tennessee 37232

CM101, a bacterial polysaccharide exotoxin produced by group B Streptococcus (GBS), also referred to as GBS toxin, has been shown to target pathological neovasculature and activate complement (C3), thereby inducing neovascularitis, infiltration of inflammatory cells, inhibition of tumor growth, and apoptosis in murine tumor models. Data from refractory cancer patients in a Phase I clinical trial with CM101 indicated a similar mechanism of tumor-targeted inflammation. To further our understanding of the mechanism of action of CM101 as an antitumor agent, we examined the role of the inflammatory response in inducing tumor apoptosis in a normal mouse and tumor-bearing mouse model. The i.v. infusion of CM101 into B16BL-6 melanoma tumor-bearing mice elevated p53 mRNA in circulating leukocytes as measured by reverse transcription-PCR, and immunohistochemistry demonstrated infiltration and sequestration of leukocytes. Whole tumor lysates from excised tumors exhibited an increase in binding to the murine p21^Waf1/Cip1-derived p53 DNA binding sequence compared with control whole tumor lysates, in which minimal or no DNA binding was observed. CM101 infusion led to elevated levels of Fas protein within the tumors as well as a decrease in the expression of fas ligand (fasL). Furthermore, tumors were apoptotic as determined by terminal deoxynucleotidyl transferase-mediated nick end labeling and DNA fragmentation assays. Collectively, these data suggest that CM101 up-regulates p53 in tumor-infiltrating leukocytes, initiating a loss of tumor immunoprivilege and consequently rendering the tumor sensitive to Fas/fasL-mediated apoptosis. CM101 induced loss of tumor immunoprivilege through changes in the expression of leukocyte p53, tumor Fas and fasL coupled with neovascularitis and leukocyte infiltration, constitutes a plausible molecular pathway for tumor reduction observed in cancer patients.

This article has been cited by other articles:

				A. M. Iga, S. Sarkar, K. M. Sales, M. C. Winslet, and A. M. Seifalian Quantitating Therapeutic Disruption of Tumor Blood Flow with Intravital Video Microscopy Cancer Res., December 15, 2006; 66(24): 11517 - 11519. [Abstract] [Full Text] [PDF]

				E. Bremer, B. t. Cate, D. F. Samplonius, L. F. M. H. de Leij, and W. Helfrich CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia Blood, April 1, 2006; 107(7): 2863 - 2870. [Abstract] [Full Text] [PDF]

				R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]

				C. Fu, S. Bardhan, N. D. Cetateanu, B. D. Wamil, Y. Wang, H.-P. Yan, E. Shi, C. Carter, C. Venkov, F. M. Yakes, et al. Identification of a Novel Membrane Protein, HP59, with Therapeutic Potential as a Target of Tumor Angiogenesis Clin. Cancer Res., December 1, 2001; 7(12): 4182 - 4194. [Abstract] [Full Text] [PDF]